Cargando…
Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center
Dupilumab is one of a number of biologics currently under investigation for the treatment of eosinophilic esophagitis (EoE). We report on a group of 7 pediatric and young adult patients with EoE who were treated with dupilumab for a primary indication of asthma or atopic dermatitis, all of whom prev...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158365/ https://www.ncbi.nlm.nih.gov/pubmed/37168913 http://dx.doi.org/10.1097/PG9.0000000000000180 |
_version_ | 1785036913869062144 |
---|---|
author | Syverson, Erin Phillips Rubinstein, Eitan |
author_facet | Syverson, Erin Phillips Rubinstein, Eitan |
author_sort | Syverson, Erin Phillips |
collection | PubMed |
description | Dupilumab is one of a number of biologics currently under investigation for the treatment of eosinophilic esophagitis (EoE). We report on a group of 7 pediatric and young adult patients with EoE who were treated with dupilumab for a primary indication of asthma or atopic dermatitis, all of whom previously failed swallowed topical corticosteroid therapy dietary for management of their EoE. All 7 patients demonstrated histologic improvement in their EoE while on dupilumab, with a drop in median peak esophageal eosinophil count from 50 eosinophils per high-powered field (eos/hpf) (IQR 48–95 eos/hpf) to 2 eos/hpf (IQR 0–5 eos/hpf) off swallowed topical corticosteroid. Additionally, improvements in EoE symptoms and endoscopic findings were noted. This report highlights the effectiveness of dupilumab in a group of multiply atopic pediatric and young adult patients with difficult-to-treat EoE in real world practice. |
format | Online Article Text |
id | pubmed-10158365 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101583652023-05-09 Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center Syverson, Erin Phillips Rubinstein, Eitan JPGN Rep Brief Report Dupilumab is one of a number of biologics currently under investigation for the treatment of eosinophilic esophagitis (EoE). We report on a group of 7 pediatric and young adult patients with EoE who were treated with dupilumab for a primary indication of asthma or atopic dermatitis, all of whom previously failed swallowed topical corticosteroid therapy dietary for management of their EoE. All 7 patients demonstrated histologic improvement in their EoE while on dupilumab, with a drop in median peak esophageal eosinophil count from 50 eosinophils per high-powered field (eos/hpf) (IQR 48–95 eos/hpf) to 2 eos/hpf (IQR 0–5 eos/hpf) off swallowed topical corticosteroid. Additionally, improvements in EoE symptoms and endoscopic findings were noted. This report highlights the effectiveness of dupilumab in a group of multiply atopic pediatric and young adult patients with difficult-to-treat EoE in real world practice. Lippincott Williams & Wilkins, Inc. 2022-02-25 /pmc/articles/PMC10158365/ /pubmed/37168913 http://dx.doi.org/10.1097/PG9.0000000000000180 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Brief Report Syverson, Erin Phillips Rubinstein, Eitan Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center |
title | Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center |
title_full | Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center |
title_fullStr | Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center |
title_full_unstemmed | Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center |
title_short | Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center |
title_sort | real world experience with dupilumab in eosinophilic esophagitis in children and young adults at a tertiary care pediatric medical center |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158365/ https://www.ncbi.nlm.nih.gov/pubmed/37168913 http://dx.doi.org/10.1097/PG9.0000000000000180 |
work_keys_str_mv | AT syversonerinphillips realworldexperiencewithdupilumabineosinophilicesophagitisinchildrenandyoungadultsatatertiarycarepediatricmedicalcenter AT rubinsteineitan realworldexperiencewithdupilumabineosinophilicesophagitisinchildrenandyoungadultsatatertiarycarepediatricmedicalcenter |